Why an ovary syndrome may get a new name: Men seem to have PCOS, too - Summary - MDSpire

Why an ovary syndrome may get a new name: Men seem to have PCOS, too

  • By

  • Annalisa Merelli

  • April 1, 2026

  • 0 min

Share

Objective:

To explore the implications of polycystic ovary syndrome (PCOS) in male health and reconsider the condition's nomenclature and diagnostic criteria, emphasizing a broader understanding of its metabolic implications.

Key Findings:
  • PCOS is often mischaracterized, focusing too narrowly on ovarian symptoms while neglecting metabolic aspects that can affect both genders.
  • The condition can manifest in males through metabolic disruptions, suggesting a broader familial link and the need for awareness in male health.
  • Current diagnostic criteria lead to both over- and under-diagnosis of PCOS, impacting treatment options for all affected individuals.
Interpretation:

The traditional understanding of PCOS is limited and does not adequately encompass its metabolic nature or its potential effects on male health, which could hinder effective treatment.

Limitations:
  • The article does not provide empirical data on the prevalence of male symptoms related to PCOS, highlighting a gap in research.
  • The proposed name changes for PCOS may face resistance within the medical community, indicating a need for broader consensus and education.
Conclusion:

There is a need for a paradigm shift in how PCOS is defined and diagnosed, recognizing its metabolic implications and potential male manifestations to improve health outcomes.

Original Source(s)

Why an ovary syndrome may get a new name: Men seem to have PCOS, too

  • by Annalisa Merelli

  • April 1, 2026

Related Content

Correction: The role of gut microbiota mediated ferroptosis in PCOS and the therapeutic potential of Chinese herbal medicine

Sleep Study Cutoffs May Guide Discharge

Preoperative sleep study values may distinguish lower-risk children within a population for whom overnight admission is currently routine.

GLP-1 Drugs Tied to Lower Addiction Risk

In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.